Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

2670
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
07:33a SANOFI : PULMATRIX, INC. : Change in Directors or Principal Officers, Financial ..
04:09a Harvard Apparatus Regenerative Technology Taps James McGorry as New CEO
06/29 Bank controls add to headaches for Greece's pharmacists
06/29 Drugmakers warn Greek medicine supply 'may be in jeopardy'
06/29 SANOFI : Pasteur and Merck Vaccines appoint David Khougazian as President of San..
06/26 Harvard Apparatus Regenerative Technology Appoints James McGorry as New Chief..
06/26 Alnylam Releases New Positive Clinical Data for ALN-AT3
06/26 New Sanofi CEO to unveil five-year plan in November - unions
06/24 SANOFI : Information concerning the total number of voting rights and shares, pr..
06/22 SANOFI : initiates diabetes training program for professionals
Advertisement
Chart
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials